See also Tani Y, Tokuda M, Nishimoto N, Yokoi H, Izumori K
The third habit is a gentler relationship with food
semaglutide and tirzepatide each have distinct clinical profiles that make one a better fit depending on your situation
First of all, its important to note that the Food and Drug Administration (FDA) does not review or approve dietary supplements for how safe or effective they may be (though brands are prohibited from marketing products that are adulterated or misbranded. Vitamins will have a date on the label, but it doesnt mean that they are automatically expired on that day
Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications primarily prescribed for type 2 diabetes management and, in some formulations, for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

For type 2 diabetes management , licensed GLP-1 medications include: Exenatide (Byetta, Bydureon) available as twice-daily or once-weekly formulations Liraglutide (Victoza) administered once daily Dulaglutide (Trulicity) given once weekly Semaglutide (Ozempic) administered once weekly as an injection Semaglutide (Rybelsus) taken orally once daily (for type 2 diabetes only, not licensed for weight management) For weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities, two medications hold specific licences: Liraglutide 3.0 mg (Saxenda) once-daily subcutaneous injection Semaglutide 2.4 mg (Wegovy) once-weekly subcutaneous injection Access to these medications through the NHS is governed by NICE guidance